Penumbra (PEN)
(Delayed Data from NYSE)
$233.30 USD
+4.43 (1.94%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $233.26 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$233.30 USD
+4.43 (1.94%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $233.26 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Here's Why Investors Should Hold Luminex (LMNX) Stock Now
by Zacks Equity Research
Luminex (LMNX) gains from strength in the Aries platform. However, cutthroat competition in the life sciences industry is worrisome.
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
4 Stocks That Had Massive Earnings Surprises in 2018
by Ankita Gupta
Given the market volatility, let's take a look at four stocks that survived the onslaught and even surpassed market expectations.
Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com
by Zacks Equity Research
Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com
OrthoPediatrics (KIDS) Catches Eye: Stock Jumps 10.3%
by Zacks Equity Research
OrthoPediatrics (KIDS) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
In Search of an Earnings Beat? Play These Top 5 Stocks
by Sanghamitra Saha
These top-ranked stocks may surpass bottom-line estimates in their next release.
Is Penumbra (PEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (PEN) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Papa Murphy's, Penumbra, Tesla, Ameren and Arbor Realty
by Zacks Equity Research
Zacks.com featured highlights include: Papa Murphy's, Penumbra, Tesla, Ameren and Arbor Realty
5 Low-Beta Stocks to Beat Market Volatility
by Zacks Equity Research
We have developed a strategy to show that securities with lower volatility than the market can generate lucrative returns.
Is Penumbra (PEN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (PEN) Outperforming Other Medical Stocks This Year?
DexCom (DXCM) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
DexCom (DXCM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Penumbra (PEN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 466.67% and 9.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Penumbra (PEN) closed at $138.53, marking a +0.2% move from the previous day.
Is Penumbra (PEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (PEN) Outperforming Other Medical Stocks This Year?
Penumbra (PEN) Stock Moves -1.17%: What You Should Know
by Zacks Equity Research
Penumbra (PEN) closed at $140.68 in the latest trading session, marking a -1.17% move from the prior day.
Penumbra (PEN) Stock Moves -1.9%: What You Should Know
by Zacks Equity Research
Penumbra (PEN) closed at $131 in the latest trading session, marking a -1.9% move from the prior day.
Top Stock Picks for the Week of October 8th
by Panel Of Zacks Experts
Two Technology Companies With Different Focus.
Accelerate Diagnostics (AXDX) Surges: Stock Moves 6% Higher
by Zacks Equity Research
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
by Zacks Equity Research
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
How to Invest in the Hot Medical Device Innovators
by Tracey Ryniec
Forget the biotechs. Medical device companies are innovating in amazing ways. Here's how to invest.
Tandem Diabetes Care (TNDM) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Tandem Diabetes Care (TNDM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Penumbra, Facebook, Softbank, Sony and Honda Motor highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra, Facebook, Softbank, Sony and Honda Motor highlighted as Zacks Bull and Bear of the Day